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Introduction
Immune cells harboring transcriptionally silent HIV-1 (HIV) are 
not detected by the host immune system in HIV-infected indi-
viduals with suppressive antiretroviral therapy (ART) and pose a 
major barrier to HIV eradication (1–6). HIV transcription is high-
ly regulated and is responsive to several cell signaling pathways. 
Transcriptional activation of latent HIV has been reported using 
latency reversal agents (LRAs) that activate protein kinase C/
NF-κB and pTEFb signaling (7). It has been well recognized that 
epigenetic regulation of histone tails at the HIV long-terminal 
repeat (LTR) is critical for the establishment of latent reservoirs 
(8). Recent studies showed that inhibition of histone deacetylase 
(HDAC) or histone methyltransferase can reactivate HIV, and 
some of these inhibitors have been investigated as LRAs in human 
clinical trials (9–14). While HDAC inhibitors can reactivate latent 
HIV, their potency is low compared with those of other LRAs (7, 15, 
16). The landscape of epigenetic modifications at the HIV LTR reg-
ulating viral transcription or latency is not fully defined. Addition-
al unknown epigenetic modifications may exist that limit efficient 
HIV reactivation. Elucidation of these novel epigenetic modifica-
tions will provide a better understanding of viral transcriptional 
regulation and identify novel targets for drug discovery.
A recently discovered histone posttranslational modification 
by lysine crotonylation is involved in regulating host gene expres-
sion (17, 18). Histone crotonylation at the gene promoter can be 
induced by increasing of intracellular levels of crotonyl-CoA 
through the addition of sodium crotonate (Na-Cro) to cells (18, 
19). However, it is not known whether histone crotonylation is 
involved in HIV transcription and whether it interacts with or 
influences other histone modifications at the HIV LTR that may be 
important for efficient HIV transcription. Similar to histone acetyl-
ation marks, several “writers” of histone crotonylation have been 
reported (20–22), including the crotonyl-CoA–producing enzyme 
acyl-CoA synthetase short-chain family member 2 (ACSS2).
The gastrointestinal tract, where the ACSS2 enzyme is an 
essential component of fatty acid metabolism, plays an import-
ant role in lipid homeostasis (23). It has been reported that HIV 
infection leads to lipid dysregulation (24–26), and we and others 
have reported that lipid metabolism was altered or dysregulated 
in HIV-infected primary CD4+ T cells as well as in intestinal tis-
sues from individuals with early HIV infection (27–29). Interest-
ingly, aberrant fatty acid metabolism is associated with immune 
dysregulation and nutritional complications in HIV patients with 
advanced disease (30–32). However, linkage between the changes 
in the fatty acid metabolism encompassing ACSS2 expression and 
HIV transcription and latency during the course of HIV disease 
has not been well investigated.
In this report, we demonstrate that histone crotonylation at 
the HIV LTR regulates HIV transcription and is involved in the 
establishment of HIV latency. The ACSS2 enzyme of fatty acid 
metabolism promotes histone crotonylation at the HIV LTR, lead-
ing to the reactivation of latent HIV and viral transcription in vitro 
and ex vivo, while suppression of ACSS2 inhibits HIV replication 
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ported the reversal of HIV latency ex vivo (Figure 1B). Interesting-
ly, cells from the first donor (UNC-1) were not responsive to either 
SAHA (vorinostat)  or Na-Cro, maybe because of a relatively lower 
proviral reservoir in comparison with the other patients.
Since the analysis of epigenetic marks from relatively a very 
small number of latently HIV-infected cells in vivo is challeng-
ing, we expanded the analysis of histone crotonylation for latent 
HIV reactivation to 2 well-characterized cell line models of HIV 
latency, J-Lat A1 cells (derived from Jurkat cells harboring 1 copy 
of HIV LTR-Tat-GFP gene) and U1 cells (a U937 promonocytic 
cell line harboring HIV genome with defective Tat gene). Simi-
lar to our findings in primary CD4+ T cells, addition of Na-Cro to 
J-Lat A1 cells resulted in 70-fold increased expression of ACSS2
(Figure 1C). HIV LTR–driven viral transcription was induced in a
dose-dependent manner, and Na-Cro increased HIV transcrip-
tion 9- to 12-fold in comparison with untreated controls (Figure
1D). Minimal cellular toxicity was observed with concentrations of 
Na-Cro ranging from 10 to 40 mM (Figure 1E). Similar effects of
crotonylation were observed in the U1 latent HIV cell line model
(Supplemental Figure 1). To determine the role of ACSS2 in the
replication of HIV, we used ACSS2-specific siRNA to suppress the 
and reactivation of latent HIV. Our data suggest that ACSS2- 
induced histone crotonylation is a novel epigenetic mark regulat-
ing viral transcription and may be an attractive target for develop-
ing new strategies for HIV eradication.
Results
Induction of histone crotonylation reactivates HIV from latency. 
Inducing crotonylation at histone tails in target genes by the addi-
tion of Na-Cro resulted in transcriptional activation (18). We sought 
to examine the effects of histone crotonylation in primary human 
CD4+ T cells. Expression of the crotonyl-CoA–converting enzyme 
ACSS2, at both the protein and the mRNA level, was induced in the 
primary CD4+ T cells from healthy HIV-negative donors following 
the addition of Na-Cro to the cultures (Figure 1A). To examine the 
effect of ACSS2 induction on HIV reservoirs, resting CD4+ T cells 
were isolated from peripheral blood of HIV-infected individuals 
(n = 5) with undetectable plasma viral loads (Supplemental Table 
1; supplemental material available online with this article; https://
doi.org/10.1172/JCI98071DS1). Replication-competent HIV was 
recovered from the cells of 4 of the 5 HIV-infected donors follow-
ing exposure to Na-Cro, suggesting that induction of ACSS2 sup-
Figure 1. Induction of ACSS2 reactivates HIV from latency in vitro and ex vivo. (A) Expression of ACSS2 was induced in Na-Cro-treated primary CD4+ T cells 
from HIV-negative healthy donors (n = 5). Levels of ACSS2 protein (upper panel) or mRNA (lower panel) were induced in the primary CD4+ T cells after incu-
bation with Na-Cro for 6 hours. **P < 0.01 vs. control treatment. (B) Induction of ACSS2 reactivated latent HIV in the resting CD4+ T cells from HIV-infected 
individuals (n = 5) under suppressive ART. Virus expression was compared using quantitative viral outgrowth assay in patients after the resting CD4+ T cells 
were treated with IL-2, IL-2 plus PHA, IL-2 plus vorinostat, or IL-2 plus Na-Cro. IUPM, infected units per million. (C) Na-Cro (30 mM) induced the expression of 
ACSS2 enzyme in J-Lat A1 cells after 4-hour incubation. **P < 0.01 vs. control treatment (n = 3). (D) Induction of ACSS2 by Na-Cro reactivated HIV transcrip-
tion in a dose-dependent manner in J-Lat A1 cells as measured by quantitative reverse transcriptase PCR (RT-qPCR). ***P < 0.001 vs. control treatment (n = 
4). (E) Cellular toxicity was evaluated by flow cytometry after live/dead staining (n = 4). (F) Expression of ACSS2 was suppressed following siRNA knockdown 
of ACSS2. Expression of ACSS2 was measured by real-time PCR following transfection of ACSS2 siRNA into TZM-bl reporter cells. **P < 0.01 versus control 
treatment. (G and H) Knocking down ACSS2 suppressed HIV replication in the TZM-bl reporter cell line using luciferase reporter assay without (G) or with (H) 
Na-Cro treatment. *P < 0.05 versus control siRNA knockdown (n = 3). The data were analyzed with a Student’s t test or 1-way ANOVA.
even at low Na-Cro concentrations (Figure 2A). These data sug-
gested that induction of ACSS2 following addition of Na-Cro leads 
to global reprogramming of histone tails in CD4+ T cells. However, 
it did not alter expression of transcription factors essential for HIV 
transcription except for a minimal change in the CDK9 protein 
levels (Figure 2B). Evaluation of chromatin remodeling in the HIV 
LTR by chromatin immunoprecipitation (ChIP) assay showed that 
induction of ACSS2 increased the crotonylation and acetylation of 
histone tail at H3K4 but decreased trimethylation of histone tail at 
H3K27 in the HIV LTR (Figure 2, C–E).
In agreement with our previous findings and other reports, 
we found that inhibition of histone methyltransferase (EZH2) 
by GSK343 or inhibition of DNA methyltransferase by 5-aza-2′ 
deoxycytidine (AZA-dC) minimally reactivated latent HIV (7, 33). 
Induction of ACSS2 by Na-Cro or suppression of HDAC by vori-
nostat had similar effects in reactivating latent HIV in J-Lat A1 
cells, and these findings were comparable to data from the resting 
CD4+ T cells from HIV-positive patients under ART (Figure 2F). To 
further verify the role of histone crotonylation in the maintenance 
of HIV latency, we pharmacologically suppressed the activity of 
ACSS2 using AR12, a known ACSS2 inhibitor, and investigated the 
expression of ACSS2 in the HIV LTR reporter cell line TZM-bl (a 
CXCR4-positive HeLa cell line engineered to express CD4 and 
CCR5 constitutively and firefly luciferase under the control of the 
HIV LTR). A significant reduction was detected in the HIV LTR–
driven luciferase expression in the ACSS2 siRNA–treated TZM-bl 
cells as compared with the cells treated with control siRNA, with 
or without Na-Cro treatment (Figure 1, F–H). Collectively, our 
data demonstrate that induction of ACSS2 is effective in disrupt-
ing HIV latency across multiple models of HIV latency ex vivo and 
in vitro and crotonylation-mediated transcription of HIV was pre-
dominantly driven by ACSS2.
ACSS2 enzyme leads to chromatin reprogramming through his-
tone crotonylation. To determine the molecular mechanism of 
ACSS2-induced reactivation of latent HIV, we examined sever-
al histone modifications in Na-Cro–treated T cells and assessed 
expression of major components of transcription factors involv-
ing HIV transcription and viral latency. Interestingly, induction of 
ACSS2 increased not only H3K4 crotonylation (H3K4cr) but also 
H3K4 acetylation (H3K4Ac) and H3K18 acetylation (H3K18Ac). In 
contrast, it markedly decreased H3K27 trimethylation (H3K27Me). 
Changes in histone crotonylation and acetylation were detectable 
Figure 2. Histone crotonylation by ACSS2 induction reprograms histone tails at the HIV LTR, and suppression of ACSS2 dampens reactivation of latent 
HIV. (A) Induction of ACSS2 increased global expression of H3K4 crotonylation (H3K4Cr), H3K4 acetylation (H3K4Ac), and H3K18 acetylation (H3K18Ac) while 
decreasing expression of H3K27 methylation (H3K27Me) after Na-Cro treatment for 4 hours in J-Lat A1 cells. Immunoblots are representative of 3 indepen-
dent experiments. (B) Protein expression after Na-Cro treatment for 4 hours in J-Lat A1 cells. Immunoblots are representative of 3 independent experiments. 
(C–E) Na-Cro addition induced histone crotonylation at H3K4 (C) and histone acetylation at H3K4 (E) while suppressing histone trimethylation at H3K27 (D) 
at the HIV LTR. ChIP assay was performed using anti-H3K4Cr (n = 3), anti-H3K4Ac (n = 3), and anti-H3K27Me3 (n = 6) antibodies after J-Lat A1 cells were 
treated with 30 mM Na-Cro for 4 hours. PCR primers were specific for the HIV LTR region. **P < 0.01 versus control treatment. (F) Reactivation of latent HIV 
was examined using different epigenetic modifiers. J-Lat A1 cells were treated with 30 mM Na-Cro, 500 nM vorinostat, 2 μM GSK343, or 5 μM AZA-dC. HIV 
expression was measured by RT-qPCR. **P < 0.01 and ***P < 0.001 versus control treatment (n = 3). (G) Pretreatment with the ACSS2 inhibitor AR12  
(5 μM for 30 minutes) dampened histone crotonylation–induced reactivation of latent HIV. ***P < 0.001 versus control treatment; ###P < 0.001 versus 
Na-Cro treatment (n = 4). (H) Suppression of ACSS2 by AR12 decreased histone crotonylation at the HIV LTR. J-Lat A1 cells were pretreated with 5 μM AR12 
for 30 minutes, followed by Na-Cro (20 mM) addition and incubation for 4 hours. Crotonylation of H3K18Cr at the HIV LTR was measured by ChIP assay.  
**P < 0.01 versus control treatment; ##P < 0.01 versus Na-Cro treatment (n = 3). The data were analyzed with a Student’s t test or 1-way ANOVA.
matin remodeling by inhibiting histone deacetylation (12). A com-
bination of Na-Cro with the bromodomain protein BRD4 inhibitor 
JQ1, the histone methyltransferase inhibitor GSK343, or the DNA 
methyltransferase inhibitor AZA-dC (7, 36) did not show any syner-
gistic effect on HIV reactivation in J-Lat A1 cell lines. It is intriguing 
to note that pretreatment with Na-Cro followed by vorinostat treat-
ment demonstrated a synergistic effect on HIV reactivation (Figure 
3A). In contrast, pretreatment with vorinostat followed by Na-Cro 
failed to show any combination effect in either J-Lat A1 cells or U1 
cell models of HIV latency (Figure 3B and Supplemental Figure 
2B). Since a combination of Na-Cro and PEP005 displayed the 
most potent effect on reactivation of latent HIV, we further sought 
to measure the magnitude of HIV LTR reactivation. A significant 
level of viral reactivation was detected by flow cytometric analy-
sis (Figure 3C). Similarly, a synergistic increase in HIV reactivation 
was also identified in U1 monocytic cells (Figure 3D).
Induction of ACSS2 has no impact on immune activation. We 
examined whether induction of histone crotonylation in T cells 
impacted the level of immune activation in these cells. Peripheral 
blood mononuclear cells from HIV-negative healthy donors (n = 5) 
were treated with PMA/ionomycin or Na-Cro for 24 or 72 hours. 
Changes in the immune cell status were examined by measure-
ment of the levels of HLA-DR, CD69, and PD-1 in the T cell sub-
sets by flow cytometric analysis (Supplemental Figure 3). Among 
CD3+, CD4+, or CD8+ T cells, Na-Cro–induced histone crotonyla-
tion had no effect on the expression of those immune activation 
or checkpoint markers. In contrast, PMA/ionomycin treatment 
significantly induced CD69, HLA-DR, and/or PD-1 expression 
(Supplemental Figure 3, A–C). These findings suggest that histone 
crotonylation by induction of ACSS2 does not cause changes in T 
cell activation or suppression.
downstream effects on HIV transcription (34). Induction of ACSS2 
by Na-Cro had 8-fold higher HIV reactivation compared with the 
untreated control. In contrast, addition of the ACSS2 inhibitor 
AR12 resulted in a substantial decrease in latent HIV reactivation 
(>60%). Thus, pretreatment with AR12 diminished the effects of 
ACSS2 induction in disrupting HIV latency (Figure 2G). Impor-
tantly, pharmacologic inhibition of the ACSS2 enzyme markedly 
dampened histone crotonylation at HIV LTR (Figure 2H). Col-
lectively, our data show that ACSS2-driven histone crotonylation 
at HIV LTR remodeled the histone tails to reactivate HIV from 
latency. These data identify a new mechanism that maintains HIV 
latency through limitation of ACSS2, thereby reducing histone 
crotonylation at the HIV LTR.
ACSS2 reactivates HIV synergistically with other LRAs. The estab-
lishment and maintenance of HIV latency involve several molecu-
lar signaling pathways. Therefore, an efficient reactivation of latent 
HIV in the “shock-and-kill” approach may require the use of a com-
bination of LRAs targeting different viral latency mechanisms. We 
sought to determine whether an intervention to induce histone 
crotonylation to reactivate latent HIV was synergistic with other 
LRAs that have different mechanisms of action. In combination 
treatments, J-Lat A1 cells were pretreated with Na-Cro, followed 
by treatment with other LRAs. Our data showed that crotonylation 
by Na-Cro addition was synergistic with PEP005, bryostatin-1, or 
vorinostat in reactivating latent HIV. Combination with Na-Cro 
increased reactivation of latent HIV 8-fold, 3.3-fold, and 2.0-fold 
compared with single treatment of PEP005, bryostatin-1, or vori-
nostat (Figure 3A and Supplemental Figure 2A). The protein kinase 
C (PKC) agonists PEP005 and bryostatin-1 have been shown to 
reactivate HIV through the PKC/NF-κB pathway (7, 35). Vorinostat 
is an HDAC inhibitor that activates HIV expression through chro-
Figure 3. A synergistic reactivation of latent HIV 
expression by the histone crotonylation in combi-
nation with other LRAs. (A) The J-Lat A1 cells were 
treated overnight with 30 mM Na-Cro (n = 3), 6 nM 
PEP005 (n = 3), 2 μM JQ1 (n = 4), 10 nM bryostatin (n = 
4), 250 nM vorinostat (n = 3), 2 μM GSK343 (n = 4), 5 
μM AZA-dC (n = 4), or 5 ng/ml PMA (n = 4) individually 
or in combination as indicated in the panel and eval-
uated for HIV reactivation by RT-qPCR. *P < 0.05 and 
***P < 0.001 versus LRA alone. (B) The J-Lat A1 cells 
were pretreated with 250 nM of vorinostat; then 40 
mM of Na-Cro was added overnight. The HIV reactiva-
tion was measured by real-time PCR. **P < 0.01 and 
***P < 0.001 versus control treatment (n = 3). NS, not 
significant compared with Na-Cro treatment alone. (C) 
Effect of 30 mM Na-Cro, individually or in combina-
tion with PEP005, on reactivation of latent HIV was 
tested. The cells were treated overnight, and J-Lat A1 
cells with HIV reactivation were measured by detection 
of GFP-expressing cells using flow cytometry. ***P < 
0.001 versus control treatment; ###P < 0.001 versus 
PEP005 alone (n = 3). (D) U1 cells were treated similarly 
as in C; RT-qPCR was performed to measure viral 
expression. ***P < 0.001 vs. untreated control; ###P < 
0.001 versus PEP005 treatment alone (n = 3). The data 
were analyzed with 1-way ANOVA.
initiation of HIV transcripts in primary CD4+ T cells from 5 of 6 
patients and elongation of HIV transcripts in 4 of 6 patients (Fig-
ure 4, A–C). Treatment with PEP005 induced the initiation of HIV 
transcription in CD4+ T cells from all 6 patients, while the elon-
gation of long viral transcripts was detected in 5 of 6 patient sam-
ples. In agreement with our previous reports, PEP005 alone also 
induced full-length transcription of HIV in most patient samples 
(5 of 6 samples) (7). These data demonstrate the ability of histone 
crotonylation by ACSS2 induction to reactivate HIV from latency 
in primary CD4+ T cells from HIV-infected patients under sup-
pressive ART. A combination of ACSS2 induction with PEP005 in 
primary CD4+ T cells from HIV-infected patients induced greater 
reactivation of latent HIV than either agent alone (Figure 4, A–C) 
and exceeded levels induced even by PMA/ionomycin treatment 
in most of the patient samples, indicating a significant potency of 
this combination treatment (Supplemental Figure 4). An analysis 
of synergy using the Bliss independence model confirmed that the 
combination of PEP005 and Na-Cro synergistically reactivates 
latent HIV ex vivo (Figure 4D, Supplemental Figure 5, and ref. 39). 
These findings are in agreement with our data from HIV latency 
Induction of histone crotonylation in combination with other 
LRAs disrupts HIV latency in primary CD4+ T cells ex vivo. In HIV 
latency cell culture models in vitro, we found that Na-Cro dis-
played the greatest synergy for HIV reactivation in combination 
with the PKC agonist PEP005 as compared with other LRAs (Fig-
ure 3A and Supplemental Figure 2A). We sought to validate this 
finding in the ex vivo primary CD4+ T cells from HIV-infected 
patients. Peripheral blood samples were obtained from 6 HIV- 
infected patients receiving suppressive ART. They had undetect-
able plasma viral loads (<20 copies/ml plasma) and greater than 
400 CD4+ T cell number per microliter of blood (465–885 cells/μl) 
(Supplemental Table 1, patients 1–6). Primary CD4+ T cells were 
treated with PMA/ionomycin, PEP005, Na-Cro, or PEP005 in 
combination with Na-Cro for 6 hours. HIV transcription following 
viral reactivation was measured by digital droplet PCR targeting 
the TAR region (initiation), long LTR region (proximal elongation), 
or poly(A) region (completed transcription) of the HIV genome 
(7, 37, 38). In concordance with the findings from resting CD4+ 
T cells using quantitative viral outgrowth assay ex vivo and from 
HIV latency cell models in vitro, histone crotonylation induced 
Figure 4. Histone crotonylation modifier and PEP005 synergistically reactivate latent HIV in CD4+ T cells from HIV-infected individuals under sup-
pressive ART. (A–C) Primary CD4+ T cells isolated from HIV-positive patients (n = 6) under ART were treated with 100 ng/ml PMA plus 2 μM ionomycin, 
12 nM PEP005, 40 mM Na-Cro, or 12 nM PEP005 combined with 40 mM Na-Cro for 6 hours. Viral transcription from total RNA was analyzed by reverse 
transcriptase digital droplet PCR with primers targeting initiation (TAR region) (A), elongation (long LTR) (B), or full transcription [poly(A) region] (C) of 
the HIV genome. (D) Na-Cro synergistically reactivates the latent HIV with PEP005 in primary CD4+ T cells isolated from patients under suppressive ART. 
The difference between the observed fraction and predicted fraction or faxyo-faxyp (Δfaxy) was determined by Bliss independence analysis from 6 patient 
samples as described in the Supplemental Methods. **P < 0.01 and ***P < 0.001 versus faxyP (n = 6).
cell culture models in vitro (Figure 3). While the combination of 
Na-Cro with vorinostat (SAHA) increased reactivation of latent 
HIV compared with vorinostat alone in 4 of 6 primary CD4+ T cell 
samples isolated from patients under suppressive ART, synergy 
was not observed (Supplemental Figure 6). Therefore, the impact 
of crotonylation on acetylation-induced latent HIV reactivation 
warrants further investigation. Collectively, our data suggest that 
histone crotonylation by ACSS2 induction is not only able to reac-
tivate the latent HIV in primary CD4+ T cells from HIV-infected 
patients under ART but demonstrates synergism with PEP005, an 
LRA targeting PKC/NF-κB signaling, in its reactivation activity.
ACSS2 is induced during acute SIV infection in the rhesus macaque 
model of AIDS in vivo. As shown above, the induction of ACSS2 
results in chromatin remodeling via crotonylation of histone tails 
at the HIV LTR; the latter drives the replication of HIV or reacti-
vates HIV from latency in vitro and ex vivo. To determine whether 
viral infection affects ACSS2 expression in vivo, we examined the 
expression of ACSS2 in intestinal tissues during viral infection in 
the SIV-infected rhesus macaque model of AIDS (Supplemental 
Table 2). We found that ACSS2 expression was highly induced in 
the intestine during the primary acute SIV infection in vivo. How-
ever, the ACSS2 levels decreased during the chronic stage of viral 
infection (Figure 5A). These findings suggest that ACSS2 may 
influence viral replication in vivo. Interestingly, ACSS2 is one of 
the essential enzymes for controlling lipid or fatty acid metabo-
lism (19, 40). To determine whether lipid or fatty acid metabolism 
was altered during viral infection, we analyzed the metabolic pro-
files of the luminal contents from SIV-infected rhesus macaques. 
We found that approximately 60% of the changes in the metabolic 
products during SIV infection were related to lipid metabolism. 
Within lipid metabolism, approximately 45% of the altered meta-
bolic products belonged to fatty acid metabolism (Figure 5, B and 
C). These data indicate that SIV/HIV infection–modulated fatty 
acid metabolism may be potentially involved in the regulation of 
HIV replication through induction of ACSS2 in the gut during viral 
infection in vivo.
Discussion
Latent HIV reservoirs in the host are established very early in viral 
infection (41–45). Since HIV provirus preferentially integrates in 
transcriptionally active regions of the host genome (8), it is nec-
essary to establish a quiescent chromatin microenvironment and 
Figure 5. Early SIV infection induces expression of the fatty 
acid metabolic gene ACSS2. (A) Expression of ACSS2 was 
induced in the intestinal tissues during early SIV infection. 
RNA from control (n = 4), acutely SIV-infected (1–2 weeks,  
n = 4), and chronically SIV-infected (26–28 weeks, n = 6) 
rhesus macaques was extracted, and expression of ACSS2 
was determined by RT-qPCR. ***P < 0.001 versus negative 
infection; ###P < 0.001 versus acute viral infection. The data 
were collected from 14 tissue samples and analyzed with 
1-way ANOVA. (B and C) Profiles of lipid or fatty acid metabo-
lism products during SIV infection. Metabolomic analysis was 
performed on the luminal contents from intestinal loops of 
10-week SIV-infected (n = 9 in 3 animals) or SIV-negative 
(n = 9 in 3 animals) rhesus macaques. (D) Viral infection or 
addition of crotonyl-CoA induces the expression of the fatty 
acid metabolic enzyme ACSS2, leading to epigenetic regu-
lation of HIV latency/transcription by histone crotonylation. 
Suppression of ACSS2 by siRNA or AR12 inhibits HIV replica-
tion, which may facilitate the establishment of HIV latency.
interactions among cellular and viral transcriptional regulators 
for inducing and maintaining HIV latency (9, 46). Latent HIV 
is reactivated by interference with chromatin modifications as 
evidenced by efficacy of HDAC inhibitors or EZH2 inhibitors in 
reactivation of latent HIV (16). However, the level of latent HIV 
reactivation is relatively modest in CD4+ T cell cultures in vitro 
and in ex vivo primary CD4+ T cells from HIV-infected patients 
(7, 15, 47–49). It is possible that HIV latency is regulated by addi-
tional mechanisms of histone modifications that have yet to be 
discovered. After inducing ACSS2 and histone crotonylation, the 
ability of the HDAC inhibitor vorinostat to reactivate latent HIV 
was significantly enhanced, indicating that an efficient reacti-
vation of latent HIV by HDAC inhibitors may require the croto-
nylation of histone tails at the HIV LTR. Our findings point to the 
need to further characterize the epigenetic landscape of the HIV 
LTR and investigate multiple epigenetic modifications to achieve 
optimal viral transcription or silencing. Previous studies report-
ed the ability of SIRT1 and SIRT3 proteins from the sirtuin (SIRT) 
family to erase crotonylation marks from lysine residues in HeLa 
S3 cell lines (22). However, our data did not support an essential 
role of SIRT1 or SIRT3 as a decrotonylase at the HIV LTR and 
suggest that regulation of HIV latency is independent of sirtuins 
(data not shown).
We and others have previously reported that the lipid metab-
olism was altered in HIV-infected primary CD4+ T cells in vitro 
or in the intestine during early stages of HIV infection in vivo 
(27–29). We also found that expression of the fatty acid enzyme 
ACSS2 was significantly induced in HIV-infected individuals 
following therapy interruption (50). In the current study, we 
have identified the modulation of fatty acid metabolism and the 
induction of ACSS2 expression in intestinal tissues during early 
stages of SIV infection in vivo. Aberrant fatty acid metabolism 
may activate proinflammatory signaling and disrupt mucosal 
integrity (51). It is not known whether host metabolites produced 
during HIV/SIV infection are responsible for gut mucosal dam-
age in vivo, which is under investigation. Further analysis showed 
that ACSS2 can also influence HIV replication and viral latency 
by modulating histone crotonylation at HIV LTR. Disruption of 
HIV latency was observed by histone crotonylation following 
the induction of ACSS2 in vitro and ex vivo. Therefore, our find-
ings favor a model whereby suppression of histone crotonylation 
inhibits reactivation of latent HIV and supports the maintenance 
of viral latency (Figure 5D). Previously, we found that expression 
of the ACSS2 gene was significantly induced in the intestinal 
biopsies of HIV-infected patients following interruption of ART 
in vivo (50). Our data, for the first time to our knowledge, have 
linked fatty acid metabolism to the epigenetic regulation of HIV 
transcription and maintenance of viral latency through crotonyla-
tion of histone tails by ACSS2 at the HIV LTR.
HIV RNA transcription can be detected in the absence of the 
production of virus and viral antigens and therefore may be insuf-
ficient to trigger viral cytolytic effects or immune recognition and 
clearance of reservoir cells (1, 52). Recently, Pollack et al. reported 
that even defective viruses can produce viral proteins that can be 
recognized by cytotoxic T lymphocytes (CTLs) mediating immune 
clearance (53). Detection of polyadenylated HIV RNA is consid-
ered to be the best correlate of viral production (39). In this study, 
we assessed HIV reactivation by measuring HIV transcripts rep-
resenting the viral initiation (TAR), elongation (long LTR), and 
complete transcription (polyadenylated RNA). In addition, we also 
measured HIV p24 levels in culture supernatants as a correlate of 
viral production. When induction of ACSS2 was used alone to 
reverse HIV latency, the magnitude of effects on initiation of tran-
scription was greater than that of effects on the elongation or gen-
eration of fully transcribed HIV RNA. However, detection of HIV 
p24 outgrowth from the resting CD4+ T cells in quantitative viral 
outgrowth assay indicated that the net effects of ACSS2-induced 
HIV transcription were sufficient to elicit production of viral p24 
and virus. Importantly, our data show a remarkable synergistic 
reactivation of latent HIV when histone crotonylation is combined 
with the PKC agonist PEP005, vorinostat, or JQ1 in T cell cultures 
in vitro and/or CD4+ T cells from HIV-infected patients ex vivo. A 
robust reactivation of latent HIV following the combination treat-
ment of cells from HIV-infected patients indicated that increased 
levels of viral particles could be induced that are recognized by 
CTLs for immune clearance when an effective killing strategy is 
applied. On the other hand, inhibition of histone crotonylation 
by suppression of the crotonyl-CoA–converting enzyme ACSS2 
dampened latent HIV reactivation, indicating that the loss of 
ACSS2 leads to suppression of HIV transcription and a potential 
role of histone decrotonylation in establishment of HIV latency. 
SIRT proteins were characterized as decrotonylases (22, 54). How-
ever, our data did not support their role as histone decrotonylases 
in the HIV LTR. In contrast to many if not most other LRAs, induc-
tion of ACSS2 by Na-Cro did not induce immune activation or 
modulate levels of the immune checkpoint protein PD-1 on CD4+ 
T cells or CD8+ T cells.
In summary, our data uncovered an important role for the 
fatty acid metabolic enzyme ACSS2 in the regulation of HIV tran-
scription by crotonylation of histone tails at the HIV LTR. We have 
identified decrotonylation of histone tails at the HIV LTR as a 
potential novel histone mark for establishment and maintenance 
of HIV latency. This epigenetic modification mechanism and its 
reversal open new avenues for HIV cure approaches.
Methods
Further information can be found in Supplemental Methods, available 
online with this article.
Cell culture. J-Lat A1 cells (derived from Jurkat cells harboring HIV 
LTR-Tat-GFP gene) and U1 cells (promonocytic cell line harboring 
HIV proviruses with defective Tat gene) were obtained from the NIH 
AIDS Reagent Program and cultured at 37°C with 5% CO2 in RPMI 
1640 medium containing 10% FBS and 1% penicillin/streptomycin as 
previously described (7).
Latency reversal agents. For reactivation of latent HIV, cells were 
treated with sodium crotonate (Na-Cro; Sigma-Aldrich), PEP005 
(Tocris Bioscience), vorinostat (Santa Cruz Biotechnology), GSK343 
(Sigma-Aldrich), or AZA-dC (Santa Cruz Biotechnology) for 4, 18, or 
24 hours. A combination treatment involved pretreatment of cells with 
Na-Cro for 4 hours, followed by treatment with PEP005, bryostatin-1 
(Calbiochem), JQ1 (Biovision), vorinostat, GSK343, or AZA-dC for 18 
hours. For inhibiting acyl-CoA synthetase 2 enzyme (ACSS2) and croto-
nylation, cells were pretreated with the ACSS2 inhibitor AR12 (Selleck-
chem) for 30 minutes, followed by Na-Cro treatment for 4 or 18 hours.
at day 15 and was increased in concentration at day 19. The number of 
resting CD4+ T cells in infected units per million was estimated by a 
maximum likelihood method (55).
Statistics. Data represent the mean ± SEM, calculated using all 
data points from at least 3 independent experiments. Statistical signif-
icance was determined using a 2-way Student’s t test for samples with 
only 2 groups. For multiple-comparison analysis of samples from 3 or 
more groups, we applied 1-way ANOVA analysis followed by a post-hoc 
Tukey’s test, and a P value of less than 0.05 was considered significant.
Study approval. This study was carried out under the recommen-
dations of the Public Health Service Policy on Humane Care and Use 
of Laboratory Animals. Human peripheral blood samples (n = 17) were 
obtained under informed written consent and a protocol approved by 
the Institutional Review Boards at UCD and the University of North 
Carolina at Chapel Hill. Animals were housed at the California Nation-
al Primate Research Center at UCD, and procedures were approved by 
the Institutional Animal Care and Use Committee of UCD.
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Gene knockdown by ACSS2 siRNA. TZM-bl HIV transcription/ 
replication reporter cells (1 × 105) were seeded in the 12-well plate, and 
then the cells were transfected with ACSS2 siRNA (M-010396) or non- 
targeting control siRNA (M-006526) (Dharmacon) twice. The cells 
were treated with or without 40 mM Na-Cro overnight and collected 
for luciferase assay of HIV transcription and/or lysed for quantitative 
reverse transcriptase PCR (RT-qPCR) of ACSS2 gene expression.
Primary CD4+ T cell isolation, treatment, and digital droplet PCR 
assays. Peripheral blood samples were obtained from HIV-infected 
individuals (age ranging from 22 to 62 years) on suppressive ART for 
more than 2 years (n = 12, average age 10.6 ± 5.7 years). The plasma 
viral loads were below the detection level (<20 copies/ml plasma), and 
the average CD4+ T cell number was 680.2 ± 225.6 cells/μl. The pri- 
mary CD4+ T cells were isolated using the EasySep kit (STEMCELL 
Technologies) as previously described (7, 15). The purified CD4+ T 
cells were plated at a density of 0.5 × 106 to 1 × 106 cells and treated 
with DMSO, 200 ng/ml PMA plus 2 μM ionomycin, 12 nM PEP005, 
40 mM Na-Cro, or 12 nM PEP005 plus 40 mM Na-Cro for 6 hours. 
Cell pellets were collected for RNA isolation. Initiation, elongation, or 
full transcription of HIV was analyzed with digital droplet PCR assays 
as reported before (7, 37, 38).
Quantitative viral outgrowth assay. Peripheral blood mononuclear 
cells (PBMCs) were obtained from HIV-infected individuals on sup- 
pressive ART (n = 5) by continuous-flow leukapheresis. Isolation of 
resting CD4+ T cells and quantification of replication-competent virus 
were performed as previously described (41). Briefly, approximately 
34 million to 50 million resting CD4+ T cells per each treatment con- 
dition were plated in replicate limiting dilutions of 2.5 million (18 cul- 
tures), 0.5 million (6 cultures), and 0.1 million (6 cultures) cells per 
well and stimulated for 24 hours with either (a) PHA (Remel, Thermo 
Fisher Scientific), a 5-fold excess of allogeneic irradiated PBMCs from 
a seronegative donor, and IL-2; (b) 40 mM Na-Cro plus IL-2 or 350 
nM SAHA plus IL-2; or (c) IL-2 as unstimulated control. Cultures were 
washed and cocultivated with CD8+ T cell–depleted PBMCs that were 
obtained from selected HIV-seronegative donors previously screened 
for adequate CCR5 expression. Culture supernatants were harvested 
on days 15 and 19 and assayed for virus production by p24 antigen cap- 
ture ELISA (ABL). Cultures were scored as positive if p24 was detected 
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